| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 22031 |
| Drug | Berotralstat |
| Brand | Orladeyo® |
| Indication | Routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older |
| Assessment Process | |
| Rapid review commissioned | 09/05/2022 |
| Rapid review completed | 03/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of berotralstat compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 28/03/2023 |
